ArticleClinical and vaccine immunology : CVI2011
Evaluation of the immunogenicity and biological activity of the Citrobacter freundii Vi-CRM197 conjugate as a vaccine for Salmonella enterica serovar Typhi.
Article in Clinical and vaccine immunology : CVI, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 54 citations in OpenAlex.
- Trial
- Design of a Glycoconjugate Vaccine AgainstVaccines · 2024Article
- Adjuvanted Modified Bacterial Antigens for Single-Dose Vaccines.International journal of molecular sciences · 2024Article
- Review
- Qualification of an enzyme-linked immunosorbent assay for quantification of anti-Vi IgG in human sera.Frontiers in immunology · 2024Article
- Exploring the variables influencing the immune response of traditional and innovative glycoconjugate vaccines.Frontiers in molecular biosciences · 2023Review
- A strategic model for developing vaccines against neglected diseases: An example of industry collaboration for sustainable development.Human vaccines & immunotherapeutics · 2022Review
- Article
- Article
- Generalized Modules for Membrane Antigens as Carrier for Polysaccharides: Impact of Sugar Length, Density, and Attachment Site on the Immune Response Elicited in Animal Models.Frontiers in immunology · 2021Article
- Short Vi-polysaccharide abrogates T-independent immune response and hyporesponsiveness elicited by long Vi-CRMProceedings of the National Academy of Sciences of the United States of America · 2020Article
- Article
- Structural and immunological characterization ofBioscience reports · 2018Article
- Role of Environmental Factors in Shaping Spatial Distribution of Salmonella enterica Serovar Typhi, Fiji.Emerging infectious diseases · 2018Article
- A cross-sectional seroepidemiological survey of typhoid fever in Fiji.PLoS neglected tropical diseases · 2017Article
- The influence of conjugation variables on the design and immunogenicity of a glycoconjugate vaccine against Salmonella Typhi.PloS one · 2017Article
- A modification-specific peptide-based immunization approach using CRM197 carrier protein:Molecular medicine (Cambridge, Mass.) · 2017Article
- Development of a high-throughput method to evaluate serum bactericidal activity using bacterial ATP measurement as survival readout.PloS one · 2017Article
- Differential Killing of Salmonella enterica Serovar Typhi by Antibodies Targeting Vi and Lipopolysaccharide O:9 Antigen.PloS one · 2016Article
- Design of glycoconjugate vaccines against invasive African Salmonella enterica serovar Typhimurium.Infection and immunity · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
Typhoid fever remains a major health problem in developing countries. Young children are at high risk, and a vaccine effective for this age group is urgently needed. Purified capsular polysaccharide from Salmonella enterica serovar Typhi (Vi) is licensed as a vaccine, providing 50 to 70% protection in individuals older than 5 years. However, this vaccine is ineffective in infants. Vi conjugated to a carrier protein (i.e., an exoprotein A mutant from Pseudomonas aeruginosa [rEPA]) is highly immunogenic, provides long-term protection, and shows more than 90% protective efficacy in children 2 to 5 years old. Here, we describe an alternative glycoconjugate vaccine for S. Typhi, Vi-CRM(197), where Vi was obtained from Citrobacter freundii WR7011 and CRM(197), the mutant diphtheria toxin protein, was used as the carrier. We investigated the optimization of growth conditions for Vi production from C. freundii WR7011 and the immunogenicity of Vi-CRM(197) conjugates in mice. The optimal saccharide/protein ratio of the glycoconjugates was identified for the best antibody production. We also demonstrated the ability of this new vaccine to protect mice against challenge with Vi-positive Salmonella enterica serovar Typhimurium.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.